Share Name Share Symbol Market Type Share ISIN Share Description
IQE LSE:IQE London Ordinary Share GB0009619924 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.00p +1.99% 51.25p 51.00p 51.25p 51.75p 49.50p 51.00p 10,876,219.00 16:29:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Technology Hardware & Equipment 114.0 19.4 3.0 17.1 346.29

IQE (IQE) Latest News

More IQE News
IQE Takeover Rumours

IQE (IQE) Share Charts

1 Year IQE Chart

1 Year IQE Chart

1 Month IQE Chart

1 Month IQE Chart

Intraday IQE Chart

Intraday IQE Chart

IQE (IQE) Discussions and Chat

IQE (IQE) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-03-22 17:15:0149.75250,000124,375.00O
2017-03-22 17:15:0149.67730,925363,047.16O
2017-03-22 17:15:0150.87537,000273,172.72O
2017-03-22 17:08:4151.2518,6959,580.76O
2017-03-22 17:08:4150.0534,33017,181.01O
View all IQE trades in real-time

IQE (IQE) Top Chat Posts

DateSubject
22/3/2017
08:20
IQE Daily Update: IQE is listed in the Technology Hardware & Equipment sector of the London Stock Exchange with ticker IQE. The last closing price for IQE was 50.25p.
IQE has a 4 week average price of 49.63p and a 12 week average price of 44.12p.
The 1 year high share price is 55p while the 1 year low share price is currently 16p.
There are currently 675,694,061 shares in issue and the average daily traded volume is 10,670,566 shares. The market capitalisation of IQE is £346,293,206.26.
22/3/2017
11:38
bestace: The fact that some people on here were disappointed with the results even though they exceeded broker forecasts says it all - expectations got too far ahead of reality, hence the sell off. I agree with most of toptrump1's post; in particular wireless seems to have surpassed even management's expectations given they had previously flagged mid single digit growth. However I disagree on a few points: Firstly on photonics growth. I'm not sure where £27m expectations for photonics came from, but if genuine it underlines the point about expectations being way too high. All the company told us in December was "Photonics continues to be the fastest growing business segment, enjoying strong double digit growth year on year." In the interims they also used the phrase "strong double digit growth" where photonics had grown by 45% in H1. A reasonable inference would have been to apply the same 45% figure to the H2 2015 figures to get a forecast H2 2016 of £12.5m, giving FY16 revenue of £23.2m. As it turns out that wasn't very far away from the actual H2 of £12.1m and FY16 of £22.8m. Maybe that's post hoc rationalisation, but to get to £27m would have required an increase of 69% YoY which may literally be consistent with "double digit growth", but would have required an acceleration in H2 to £16.3m, some 89% higher than H2 2015. Growth accelerating to that degree would surely have been described differently in the December trading update. Secondly on broker's forecasts. 12 months ago I reckon the brokers had 2.5p EPS pencilled in, not 3p. Prior to the December trading update they had 2.7p, which increased further to 2.9p post trading update. That's an increase of 16% over the last 12 months, still much less than the increase in share price over the same period, but then again their peers and the wider markets were re-rating upwards so to an extent it is understandable why the share price would appreciate by more than the fundamentals might have implied. Looking at those broker forecasts, and reading through the Edison notes, I think they were far more grounded in reality than some private investors. Edison said in September, when the price was 28p: "IQE’s rating still remains undemanding on a fundamental basis and relative to its peers, giving scope for further share price appreciation", then in November "Our indicative valuation range of 40-45p puts IQE on multiples that are close to the mean of our sample of listed peers", then in December "Our indicative valuation range of 45-49p... places IQE on multiples that are close to the mean of our sample." Now they are saying "... the shares look fairly priced at current levels. However, given the potential for upward earnings revisions based on commercial ramp-up of photonics projects, this higher than average rating does not seem totally unreasonable to us. We see the scope for upward price movement if greater clarity regarding the rate of volume ramp-up of photonics programmes results in estimate upgrades." That seems reasonable to me - mid to longer term price appreciation if the chips fall their way, but no reason to spike higher in the short term.
22/3/2017
00:28
toptrump1: Many successful investors and fund managers use operational cash flow as a favoured measure of how well a business is performing. IQEs rise in cash flow was just 5% in 2016 Now this would be OK for an average share but considering the meteoric rise in the share price due no doubt to the Internet tipsheets and the currency gains I really think the results are mediocre Photonics was expected to be around the 27m mark and fell short considerably CMOS hasn't got going but is early days and will take years to be profitable Wireless actually held up well and surpassed expectation and if it wasn't for that the overall result would have been poor. debt level still remains high due to increase in the Capital expenditure which is greater than the increase in revenue. Analysts views of adjusted 3p eps were known 12mths ago 3mths before the start in the share price rise and 9mths before before the new yr share tips so I have to question whether the rise has been overdone and we will get a rebalance My target is therefore 40.5p based on an Actual p/e of 15, no creative accounting and in line with its peers ave. I take no notice of housebroker or any other broker tgts, their record is extremely poor, not least with IQE through the yrs.
21/3/2017
23:59
rivaldo: This columnist believes "there could be a lot more to come" from IQE - and I agree: Http://www.fool.co.uk/investing/2017/03/21/is-iqe-plc-a-falling-knife-to-catch-after-dropping-15-today/ "A good year’s trading Headline figures include revenue growth of 16.4% compared with the previous year, adjusted diluted earnings per share increasing 15.4%, and cash from operations up 7.1%. Gross borrowings rose around 60% to stand at just over twice the level of operating profits, which looks manageable. The big question after such a stellar performance is — is there more growth to come? Chief executive Dr Drew Nelson sounds optimistic, putting the firm’s growth in revenues, profit and cash generation down to the company’s “cutting edge intellectual property”, which, he says, is delivering results through a “diverse range of growth engines.” IQE has its sights set on what it describes as “global leadership across a range of markets”, arguing that advanced semiconductor materials, such as those IQE produces, are becoming an ever more important enabler of many electronics applications. Dr Nelson reckons the firm’s strategy, underpins this year’s strong financial performance and he sees an ”exciting” outlook for the business. I can’t argue with the company’s operational and share price momentum, and wouldn’t want to bet against either. City analysts following the firm expect earnings to tick up a further 5% this year and 12% during 2018. meanwhile, at today’s share price around 51p, the forward price-to-earnings (P/E) rating for 2018 sits at just over 15. The company does not pay a dividend."
28/2/2017
12:39
rivaldo: SLX (quoted in Oz) issued an operational update yesterday about cREO technology "being advanced by IQE towards commercial deployment in several advanced semiconductor markets", including this: Http://www.silex.com.au/getattachment/61bc3c50-048c-4bed-bccf-7372f78019e8/SLX-Operational-Update-270217-(Final).pdf.aspx?ext=.pdf.ToString().Replace(%22~%22,%22%22) "2) Translucent – cREO™ Technology Silex subsidiary Translucent Inc developed a novel set of semiconductor materials known as ‘Rare Earth Oxides’ (cREOTM) for application to the manufacturing of next generation devices in the semiconductor, digital communications and power electronics industries. An exclusive License and Assignment Agreement was signed with UK-based IQE Plc (LON:IQE) on 15 September 2015. IQE is the global leader in the design and manufacture of advanced semiconductor wafer products. A license payment of ~US$1.4 million was paid to Translucent in IQE shares in March 2016, which with the increase in IQE’s share price since, are now worth ~US$3 million. The cREOTM technology was transferred in late 2015 to IQE’s Greensboro, North Carolina manufacturing facility for the completion of product development and commercialisation activities during a 30-month option period ending in March 2018. Should IQE elect to exercise the right to purchase the technology within this period, payment of US$5 million will be made. The potential commercial applications that IQE have identified for the technology may result in an attractive perpetual royalty stream of between 3% and 6% of revenues generated by IQE from use of the cREO™ technology. IQE continue to produce cREO™ templates on silicon wafers for testing in various commercial applications using two of Translucent’s production reactors. These production reactors continue to produce prototype templates for trialling within the IQE Group and select commercial partners, with initial focus on wireless communications devices and power electronics devices." There's a more detailed presentation here: Http://www.silex.com.au/getattachment/506c0204-8c09-4cf5-8ef3-34ebb8e44aad/SLX-Operational-Update-Presentation-270217-(final).pdf.aspx?ext=.pdf See slides 23-29 for the main info, particularly slide 26 illustrating cREO's uses in mobile phones, electrical appliances, lighting, solar, electric vehicles etc.
09/2/2017
21:54
tomyumgoong: Not sure I want to share this story but hey ho I'm not proud:.....I invested in ARM sometime in 2009 @ approx 90p( for the same reason I invested in IQE, they were involved in the next generation of computing....tablets and smartphones. I was a bit nieve back then). The share price rose to £4 and chatter on the bulletin boards said the PE was too high and the share price was overvalued.......I got nervous and sold out only to watch the share price rise within a few years to £11+ then eventually a buyout at £16 approx.... was I gutted?...too right I was, even though I made a tidy profit. So I suppose the moral of the story is we just don't know what will happen to the share price ...if your lucks in, your lucks in! Ps. I wanted to sell out of IQE a while ago but I kept researching and through my research I just couldn't bring myself to sell out! This is like finding Intel 40 years ago IMO. Silicon is at the end of its lifespan....compound semiconductors will enable a new wave of computers and electronics and this is just the beginning!
07/2/2017
08:58
yump: I love that when companies that have messed up or got over-hyped (that's polite) change their names. So presumably Blinkx are now a music publisher ? (Sorry, instead of over-hyped I should have said "failed to change the entire world, as promised") Anyway the IQE share price is being managed by the Grand Old Duke of York by the look of it.
06/1/2017
08:02
yump: sweetnoid Why are you quoting repeat major annual contract wins ? Amongst all your detailed knowledge, how did you miss the fact that when Kopin was taken over, the major ongoing contract with Skyworks was part of it ? Put it another way: without the renewal, the IQE share price would be up the Khyber. So its not exactly 'nice' to get another announcement - its critical. This was actually discussed twice when the Skyworks contract was up for renewal as it formed a major part of IQE revenue after Kopin Wireless and with the share price going nowhere, there were worries that the contract had not been renewed.
22/9/2016
10:03
rivaldo: Tipped in today's Shares Mag FYI: "IQE sees the light Rapid growth in Photonics to keep re-rating going CITY ANALYSTS ARE growing increasingly confident about the growth prospects of compound wafer designer IQE (IQE:AIM), with number crunchers at N+1 Singer hiking their target price for the shares by more than 20% to 35p. A return to growth on its biggest Wireless business is one reason. Half year revenue here increased 7% to £43.2 million thanks to market share gains and investment in 4G and 5G mobile networks and handsets, which typically require a greater proportion of compound silicon wafer technology. But the real kicker comes from the Cardiff-based company’s higher-value Photonics side. This feeds laser technology into several applications, such as data centre connectivity, sensing applications, healthcare, cosmetic treatments, industrial illumination, heating and fibre to premises. IQE’s wafers for Photonics applications are more rich in intellectual property (IP) than Wireless applications, meaning that IQE is becoming a more influential part of the supply chain in more profitable markets. In the first half Photonics revenues soared 45% to £10.7 million delivering adjusted operating profit of £2.73 million, or 25.5% operating margins. That compares to 11.8% margins in the Wireless unit. ‘Process improvements over the past few years have meant that the performance and cost points necessary for mass adoption are now being met, which we feel will drive sustained growth going forwards,’ says N+1 Singer analyst Oliver Kno. SHARES SAYS: 􀁓􀁔 At 30.25p the stock trades on a price to earnings (PE) multiple of 10.8-times, falling to 10.1 next year. That looks too deeply discounted in spite of the strong recent share price run. A 40p share price would still imply a 2017 PE of only 13.3."
23/10/2015
16:10
yump: I'm curious as to why IQE share price is so active. I don't mean the major ups and downs, I mean the constant 10% oscillations. Other companies of the same size often seem relatively stable. They'll sit roughly at the same level for months without the ADHD stuff.
14/11/2014
20:26
sweet karolina: Also worth a read: HTTP://www.shareprophets.com/views/8961/iqe-plc-some-additional-detail-on-transaction-with-equities-first-provided-but-significant-questions-still-to-be-answered Having on Wednesday written on the recent dealings of IQE plc (IQE) directors with Equities First Holding LLC and on the same day contacted both the company and its Nomad, Canaccord Genuity, emphasising that further information should be provided and pointing to the questions my article raised, I have had no direct response from either, but note a 12:53pm Thursday announcement “to provide… further information”. The following reviews. Firstly, having stated in its initial announcement that “the directors have entered into loan agreements and have transferred a total of 18 million existing shares as security”, it is now stated that “Dr Drew Nelson entered into a share sale and repurchase agreement with Equities First Holdings on 10th October 2014 for a total of 18 million existing shares, raising a total of £1.865 million before commissions of £55,944… As part of this overall arrangement, Phillip Rasmussen and Dr Howard Williams have agreed to enter into separate loan agreements with Dr Nelson by pledging 2.72 million shares each to Dr Drew Nelson as security for loans provided by him of £274,000 to each of them”. So “loan agreements” is now “a share sale and repurchase agreement” and the 18 million shares aren’t from “the directors” but solely Drew Nelson. This leads on to the specific questions I raised in my previous article (questions in bold, company response from its announcement in italics)... Does the cash received from Equities First exactly match the announced share purchases + the income tax obligations following the announced share options exercise? “Approximately 52% of the monies raised by the Executive Directors have already been used to fund the purchase of the shares and to satisfy income tax and NI obligations following the exercise of share options announced on 10th October... The remainder of the monies raised is intended to be used to fund further tax liabilities and NI due on the exercise of share options which are due to vest in early 2015, as well as fund further share purchases and cover any potential margin calls under the share sale and repurchase agreement. The share option exercises were part of IQE's LTIP, and the directors were under no time obligation to exercise such share options, but chose to do so at this time in order to maximise their respective shareholdings in the company.” Equities First state that “in the event of substantial decline in market value, clients can simply walk away from the loan with no additional expense because it is a non-recourse loan”, how does this tally with IQE’s “Directors are required to redeem the transferred shares at maturity when the loan is repaid at the end of the three year term”? “He is obligated to repurchase all these shares at the end of a three year term, ending on 10th October 2017”. “Under the terms of the facility, the lender is prohibited from short selling or voting the shares during the term of the loan”, what about ‘the lender’ simply selling the shares? “The agreement provides that he has transferred all title and waives his voting rights in these shares. However, as previously stated, under the terms of the agreement, EFH is prohibited from short selling or voting the shares during the term of the agreement”. “Following these purchases, the executive directors have the following interests in the equity of the company”, do they? – what about the 18 million shares “transferred”? The company publishes a table which shows shareholdings unchanged from its previous announcement though with asterisks added that “These include the 18 million shares that Dr Drew Nelson sold but retains the obligation to repurchase” and that “In aggregate, using the share and repurchase agreement and associated inter-director loans, the directors have increased their interests in the companys shares by a total of 11,841,823 shares or 38%”. That “EFH is prohibited from short selling or voting the shares during the term of the agreement” is thus likely irrelevant as it has the ability to simply sell the shares (“the agreement provides that he has transferred all title”). Indeed, together with Nelson having waived his voting rights in these shares, it doesn’t seem right to include them in stated director shareholdings – particularly with there no further clarity provided on his “obligation to repurchase” against Equities First’s “non-recourse” statement. Additionally, shares in IQE currently trade at 17p and, with it stated that “the price at which he is required to repurchase the shares is 11.4 pence per share”, this sparks thoughts of counterparty risk and other questions remain including; •The announcement notes “potential margin calls under the share sale and repurchase agreement”, what are the details of these (cloudBuy plc, for example, has provided not enough detail but some)? ; •My unanswered second question; how does the “obligation to repurchase” tally with Equities First’s “non-recourse” statement? ; •Is there any comment on the IQE share price, which from closing at 16.5p on 6th October 2014, fell to 15.25p (7th October), 13.25p (8th October), 12.75p (9th October) and 12.5p (13th October) on no announcements from the company from 17th September 2014 until 10th October 2014 (directors exercise of share options)? I’ll again be sending this to the company and Canaccord.
IQE share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170323 04:26:39